Feb 03, 2020
PTC Therapeutics Announces First Publication of Real-World Data Showing Translarnaä (ataluren) Significantly Preserves Ability to Walk for Longer in Children with Duchenne Muscular Dystrophy
Oct 04, 2019
PTC Therapeutics Announces New Real-World Analysis Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Patients with Duchenne Muscular Dystrophy
Jun 28, 2019
PTC Provides Update on Translarna(TM) (ataluren) Application for Label Expansion
Apr 29, 2019
Translarna(TM) (ataluren) is the First Therapy Approved in Brazil for Duchenne Muscular Dystrophy
Oct 06, 2018
PTC Therapeutics Announces Initial Data from Patient Registry Demonstrating Translarna(TM) (ataluren) Slows Disease Progression in Children with Duchenne Caused by a Nonsense Mutation
Jul 09, 2018
PTC Therapeutics Announces Positive Data from its Translarna(TM) Phase II Clinical Trial in Children as Young as Two Years with Nonsense Mutation Duchenne Muscular Dystrophy
Feb 20, 2018
PTC Therapeutics Receives Formal Dispute Resolution Request Decision from the FDA's Office of New Drugs
Oct 25, 2017
PTC Therapeutics Receives Complete Response Letter for Ataluren's NDA
Sep 12, 2017
Now Available in Canada: ISENTRESS® HD (raltegravir), a New Once-Daily Option, in Combination with Other Antiretroviral Agents, for the Treatment of HIV-1 Infection in Appropriate Patients
Aug 08, 2017
PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update
Jun 22, 2017
New Analyses of Translarna(TM) (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress
Jun 06, 2017
PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy